What is the prevalence of Myelofibrosis?

Myelofibrosis is considered a rare disease with an estimated prevalence of approximately 1 in 100,000 to 1.5 in 100,000 people globally. While exact figures vary, the annual incidence is generally reported at about 0.5 to 1.5 cases per 100,000 individuals, though true prevalence is likely higher due to underdiagnosis.

What is the typical age and gender distribution of Myelofibrosis?

Myelofibrosis is primarily a condition of adulthood, with a median age of onset between 65 and 70 years. While it can occur in younger adults, it is extremely rare in the pediatric population. Clinical data suggests a slight male predominance in the incidence of Myelofibrosis, though the reasons for this gender distribution remain a subject of ongoing research.

Is Myelofibrosis considered a rare disease?

Yes, Myelofibrosis is classified as a rare blood cancer, specifically a myeloproliferative neoplasm. Because the symptoms—such as fatigue, night sweats, and abdominal discomfort—can mimic other conditions, Myelofibrosis is frequently underdiagnosed or misdiagnosed in its early stages. This makes determining exact epidemiological numbers challenging, as many patients may remain asymptomatic or undiagnosed for years.

Are there factors affecting the accuracy of Myelofibrosis statistics?

Several factors contribute to the difficulty in tracking the global burden of Myelofibrosis:

• Diagnostic complexity: Requires bone marrow biopsies and specialized genetic testing (e.g., JAK2, CALR, or MPL mutations).


• Variable clinical presentation: Some patients experience "pre-fibrotic" stages where the disease is less obvious.


• Reporting gaps: Limitations in cancer registry data for non-malignant or indolent phases of the disease.


• Community insights: At DiseaseMaps.org, 16 members have shared their experience with Myelofibrosis, providing a vital, real-world perspective that complements formal clinical registries and highlights the patient journey beyond simple statistics.

Next steps

• Consult a hematologist-oncologist specializing in myeloproliferative neoplasms (MPNs).


• Request genetic testing to identify specific driver mutations associated with your diagnosis.


• Connect with the Myelofibrosis community on DiseaseMaps.org to share experiences and find peer support.


• Monitor for new clinical trials through the NIH or MPN Research Foundation.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment.

References

• Orphanet (ORPHA:602): Myelofibrosis database.


• NIH Genetic and Rare Diseases (GARD) Information Center.


• MPN Research Foundation: Understanding Myelofibrosis Prevalence.


• American Cancer Society: Overview of Myeloproliferative Neoplasms.